Product Overview
GHK-Cu is a copper peptide: a three-amino-acid chain, glycyl-histidyl-lysine, bound to a copper ion in a one-to-one complex. It is found naturally in human plasma and is studied for its role in skin remodelling, collagen synthesis and inflammatory signalling. British Dragon supplies it as a lyophilised powder in a 50 mg vial, which is a research material and not an approved medicine.
The honest summary of the evidence is that nearly everything published on this peptide comes from cell cultures, skin models or topical use. The reference sheet for the compound records that no human half-life has been established and that there is no validated human dose, so the research amounts quoted later on this page are laboratory reference points rather than clinical figures. Anyone reading a confident dosage schedule for injectable GHK-Cu is reading an estimate, not a measurement.
One practical point distinguishes this vial from other peptides in the catalogue: copper. The complex is a metal-peptide, so the solution carries a distinct blue-green tint once mixed, and users with a copper sensitivity should take that seriously. Like every peptide here, GHK-Cu does not act on the hormone axis at all, which means the hormone products in the same catalogue, including Somatrobol 100 IU, Anastrozole, Tamoxifen and Clomiphene, have no bearing on how it is handled.
The chemistry is what separates this vial from every other peptide in the same section. The chain is glycyl-histidyl-lysine, three amino acids that occur naturally in human plasma, and it is supplied as a one-to-one complex with copper(II) rather than as the bare peptide chain. In that arrangement the metal travels with the molecule and the ratio is fixed at one copper ion per chain instead of being a loose addition. That is why the material is read as a metal-peptide rather than as a generic repair peptide, and why the fill is a single defined complex with a stated stoichiometry.
Reconstitution and Research Amounts
The figures below are the research reference points recorded for this compound. No validated human dose exists.
| Reconstitution | Adding 2-5 ml of bacteriostatic water to the 50 mg vial gives roughly 10-25 mg per ml; the supplier guidance is recorded in that range |
| Research amount | 1-2 mg per day systemically in laboratory models, which is a research reference and not a human dose |
| Duration | Determined by the individual study design; no validated duration exists for human use |
| Common route in the literature | Topical application dominates the published work; data on subcutaneous use in humans is essentially absent |
| Stoichiometry | A one-to-one copper(II) complex, which is the defining feature of the molecule |
| Female | The sources consulted record no gender-specific protocol; the research references are not divided by sex |
Two checks make the vial easier to work with. Colour is the first: a one-to-one copper complex mixed at the concentrations the supplier guidance describes is blue-green, so a pale, grey or colourless liquid signals that something in the preparation is wrong. Labelling is the second: writing the volume of water added and the resulting milligrams per millilitre on the vial takes the arithmetic out of memory, and with 2 to 5 ml of solvent going into the same 50 mg fill the finished strength can differ by a factor of two and a half.
Suggested Protocols
The arrangements below follow how copper peptides are handled in research settings. Linked cards open British Dragon pages where one exists, and none of them implies a clinical use.
Positions in this part of the catalogue are described rather than combined. GHK-Cu is the copper position, the one material in the group with a metal bound to it and the one whose literature is overwhelmingly topical, while the other reparative peptides nearby are separate molecules in separate vials drawn separately. Nothing in the sources describes this complex mixed with another peptide, and the metal itself is a reason to treat it as its own material rather than as a generic member of the repair family.
What to Expect
All points below describe findings from models and topical work, because human timelines have not been established.
- No human timeline. The data is limited to models, where accelerated wound healing and wound contraction have been described.
- Collagen and matrix. Stimulation of collagen and glycosaminoglycan synthesis in fibroblasts is reported in the literature.
- Inflammation. An anti-inflammatory action is described in laboratory work rather than in patients.
- Dosing limits. With no human half-life available, any dosing calculation rests on supplier reference points alone.
- Safety gap. There is no separate human safety dataset for systemic use, only topical experience.
- Colour. A correctly mixed solution is blue-green because of the copper complex; a colourless vial suggests a different product.
- Sport status. No official WADA listing was located for this peptide, which is not the same as being confirmed as permitted, so treated as unresolved.
Side Effects and Management
Human safety data for systemic use is thin, so the items below describe what is reported and mark what is unknown.
Handling and Cold Chain
The peptide does not affect the hormone axis, so there is no recovery phase. Storage and mixing are the parts that matter.
Copper is the item to hold in mind when reading the list above. A metal-peptide complex is a different proposition for anyone with a known copper sensitivity, and the topical literature is where most human experience sits, which means the systemic picture is thinner than the local one. As a research powder the vial carries no sterility guarantee for human use, so technique, dilution accuracy and written records are the user's side of the work rather than something the product supplies.
